3-Hydroxy-3-methylglutaryl coenzyme A reductase activity and low-density lipoprotein receptor expression in diffuse-type and intestinal-type human gastric cancer

被引:35
作者
Caruso, MG [1 ]
Notarnicola, M [1 ]
Cavallini, A [1 ]
Di Leo, A [1 ]
机构
[1] Sci Inst S Bellis, Biochem Lab, I-70013 Castellana Grotte, BA, Italy
关键词
HMGCoAR; LDLR; diffuse-type GC; intestinal-type GC;
D O I
10.1007/s005350200078
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Cancer cells require more cholesterol than normal cells. This requirement may be satisfied by higher hydroxy-methyl-glutaryl coenzyme A reductase activity or low-density lipoprotein receptor expression or both. We investigated hydroxy-methyl-glutaryl coenzyme A reductase activity and low-density lipoprotein receptor expression in samples of gastric carcinoma and normal mucosa obtained from 30 patients. The samples of gastric carcinoma were divided into two categories according to Lauren's classification: diffuse-type and intestinal-type. Methods. Hydroxy-methyl-glutaryl coenzyme A reductase activity was measured by radiometric assay and low-density lipoprotein receptor expression was measured by enzyme-linked immunosorbent assay. Results. Hydroxy-methyl-glutaryl-coenzyme A reductase activity was significantly higher in neoplastic tissue than in normal mucosa, both in diffuse-type and intestinal-type gastric cancer. Low-density lipoprotein receptor levels were significantly lower in neoplastic tissue than in normal mucosa of diffuse-type gastric cancer, whereas no significant difference was present between neoplastic tissue and normal mucosa in intestinal-type gastric cancer. Hydroxy-methyl-glutaryl-coenzyme A reductase activity did not differ between intestinal-type and diffuse-type neoplastic samples, while low-density lipoprotein receptor levels were significantly higher in intestinal-type than in diffuse-type gastric cancer tissue. Conclusions. These findings show different behavior of cholesterol metabolism in the two types of gastric carcinoma and, therefore, suggest that different therapeutic strategies should be adopted.
引用
收藏
页码:504 / 508
页数:5
相关论文
共 32 条
[1]  
Borrmann R., 1926, Handbuch der speziellen pathologischen anatomie and histologie, P865
[2]  
Caruso MG, 1999, ANTICANCER RES, V19, P451
[3]  
CARUSO MG, 1993, ITAL J GASTROENTEROL, V25, P361
[4]  
Caruso MG, 2001, ANTICANCER RES, V21, P429
[5]   Molecular biology of gastric carcinoma: From laboratory to bedside [J].
Chan, AOO ;
Luk, JMC ;
Hui, WM ;
Lam, SK .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 14 (12) :1150-1160
[6]  
CORREA P, 1992, CANCER RES, V52, P6735
[7]  
Filipe M. I., 1986, GASTRIC CARCINOMA, P87
[8]   MEDICAL PROGRESS - GASTRIC-CARCINOMA [J].
FUCHS, CS ;
MAYER, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (01) :32-41
[9]  
GEBHARD RL, 1987, J LIPID RES, V28, P1177
[10]   EFFECTS OF PRAVASTATIN, A HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR, ON 2 HUMAN TUMOR-CELL LINES [J].
GEBHARDT, A ;
NIENDORF, A .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1995, 121 (06) :343-349